Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer

Palmirotta, Raffaele; Ferroni, Patrizia; Savonarola, Annalisa; Martini, Francesca; Ciatti, Filippo; Laudisi, Anastasia; Sini, Valentina; Del Monte, Girolamo; Guadagni, Fiorella; Roselli, Mario

doi:10.1016/j.thromres.2009.02.014

« Previous Next »Thrombosis Research
Volume 124, Issue 4 , Pages 403-408, September 2009

Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer☆

Raffaele Palmirotta
- Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163 Rome, Italy
Patrizia Ferroni
- Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163 Rome, Italy
- Corresponding author. Tel.: +39 06 66130425; fax: +39 06 66130407.
Annalisa Savonarola
- Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163 Rome, Italy
Francesca Martini
- Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163 Rome, Italy
Filippo Ciatti
- Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163 Rome, Italy
Anastasia Laudisi
- Medical Oncology, Department of Internal Medicine, University of Rome “Tor Vergata”, Tor Vergata Clinical Center, Viale Oxford 81, 00133 Rome, Italy
Valentina Sini
- Medical Oncology, Department of Internal Medicine, University of Rome “Tor Vergata”, Tor Vergata Clinical Center, Viale Oxford 81, 00133 Rome, Italy
Girolamo Del Monte
- San Raffaele Rocca di Papa, via Ariccia 16, 00040, Rocca di Papa, Rome, Italy
Fiorella Guadagni
- Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163 Rome, Italy
Mario Roselli
- Medical Oncology, Department of Internal Medicine, University of Rome “Tor Vergata”, Tor Vergata Clinical Center, Viale Oxford 81, 00133 Rome, Italy

Received 28 July 2008; received in revised form 3 February 2009; accepted 17 February 2009.

Abstract

Introduction

Plasminogen activator inhibitor (PAI-1) may have an independent prognostic value in breast cancer (BC). PAI-1 4G/5G polymorphism may have significance for antigen expression. Thus, we analyzed the possible associations between PAI-1 4G/5G polymorphism, plasma PAI-1 levels, and clinicopathological features of breast cancer (BC) patients.

Patients and Methods

PAI-1 4G/5G polymorphism (both on germinal and tumor DNA) and plasma PAI-1 levels were investigated in 99 BC patients and 50 unrelated healthy women similar for age and menopausal status.

Results

No association was found between allele frequencies and clinicopathological features of BC or plasma antigen levels. Plasma PAI-1 levels were higher in BC compared to controls (p=0.002), particularly in patients with large tumors (p<0.001). 5-year follow-up was achieved in 79 patients: 30% had relapsing disease, 63% with positive compared to 37% with negative PAI-1 levels (p<0.05). 5-year relapse-free survival rate of positive PAI-1 was 46% vs., 77% of negative patients (p=0.02).

Conclusions

We may conclude that plasma PAI-1 levels in BC patients could represent a useful prognostic variable for relapse, although PAI-1 polymorphism might not represent a genetic susceptibility factor.

Abbreviations: PAI-1, Plasminogen activator inhibitor, BC, breast cancer, RFS, relapse-free survival, OS, overall survival, gDNA, genomic DNA, IQR, Inter-quartile range, CTAD, citrate, theophylline, adenosine, dipyridamole, EORTC, European Organization for Research and Treatment of Cancer